Skip to main content
Equibles
AZN logo

AZN · Astrazeneca PLC

Track AZN — free

Use AZN with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about AZN

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$156.45 -0.79 (-0.50%) At close · Aug 14
Market Cap
$242.64B
Shares
1.55B

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$156.45 Open$155.50 Day$154.53–156.46 Since split$155.62–209.48 Avg vol 30d3.8M Short int1.8M · 0.1% float · 1.0d Short vol20% Last earningsApr 29, 2026 DataFeb 2026–Aug 2026

Raw chart and full-history price indicators begin at the captured split on Feb 2, 2026; bars on opposite sides are not compared.

The closing range begins at the captured split on Feb 2, 2026.

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Limited Quant / Vol Moderate
Market backdrop VIX 14.3 · calm Equity put/call 0.52
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 50-day avg −10%
below
RSI (14) 35
neutral
MACD trend Negative
52-week position 2%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −7%
trailing
6-month return −24%
trailing
Relative strength −37%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+8% holders QoQ · +274 funds added
Insider flow Distributing
Net -$2.2M over 90 days · 100% sells
Short interest Falling
0.12% of float · ▼ -27.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
1,440 holders — near 3-yr high, broad support
Squeeze score 22
low risk · 0–100
Fundamentals
Limited
Not enough data for a confident read.
Quant / Vol
risk profile
Moderate
Volatility 30%
annualized · 1-yr
Max drawdown −26%
past year
ATR 2.7%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the Earnings Call filed Mar 31, 2026
Milestone payments · full year $2.5B
Prior guidance period ended · from the Earnings Call filed Sep 30, 2025
CapEx increase for the full year versus 2024 · full year up to 50%

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 0
50 / 200-day cross
No cross Neutral
Price vs 50-day avg
−10% Bearish
RSI (14)
35 Neutral
MACD trend
Negative Bearish
52-week position
2% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50/200-day averages unavailable
Institutional flow Accumulating
+8% holders QoQ · +274 funds added
Insider flow Distributing
Net -$2.2M over 90 days · 100% sells
Short interest Falling
0.12% of float · ▼ -27.4% MoM · 1.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
1,440 holders — near 3-yr high, broad support
Price context
position in its range since split · 2026-02-02
Range low $156 Now $156 · 2% Range high $209
vs 50-day avg -10%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Drug Manufacturers - General — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
AZN
Astrazeneca PLC
this stock
$242.64B — — — 0.1%
LLY
ELI LILLY & Co
 $1.11T +9.8% +44.7% 39.6 1.0%
JNJ
Johnson & Johnson
 $627.42B +25.8% +6.0% 30.2 1.1%
ABBV
AbbVie Inc.
 $440.83B +9.2% +8.6% 70.5 1.3%
MRK
Merck & Co., Inc.
 $335.14B +29.1% +1.3% 108.7 1.1%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
1,440
% held
52.2%
Net QoQ
+54.0M sh
Top holder
INVESTOR AB
Held Float
View
Held by Funds
Fund positions
158
View
Short & Settlement
Short Interest Falling
Shares short
1.8M
Days to cover
1.0d
Change
-695.2K sh
View
Short Volume
Short vol %
20%
As of
Aug 14, 2026
Short Total
View
Fails to Deliver
FTD shares
18.7K
Value
$3.2M
As of
Jul 13, 2026
View
Off-Exchange
Off-exchange %
41.4%
Week of
Jul 6, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$2.2M
Buyers / Sellers
0 / 1
Buyers Sellers
View
Congressional Trades Buy
Member
Alan Armstrong
Amount
$1.0K–$15.0K
Traded
Mar 31, 2026
View
Filings
SEC Filings
Latest
6-K
Filed
Aug 17, 2026
This year
68
View
Proposed Sales
Value
$1.3M
Shares
15.0K
Filed
Nov 12, 2025
View
Earnings & Events
Earnings Calls
Last call
Apr 29, 2026
View

Performance

Raw-price comparisons begin at the captured split on Feb 2, 2026; windows that need an earlier baseline remain unavailable.

5D 20D 120D MTD YTD
AZN -3.1% -7.4% -23.7% -7.8% —
SPY +0.4% +4.5% +13.8% +3.9% +13.9%
vs SPY -3.5% -11.8% -37.4% -11.7% —

Capital returns

Latest dividend
$0.795 / share · ex Aug 7, 2026
Cut 63.1%
Paid (TTM)
$2.948 / share · 2 payouts
Dividend yield (TTM, derived)
— · history filling in

Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.

Key facts CIK 901832 CUSIP G0593M107 13F (30d) 1248 filings 1218 filers Visit website

Report a Problem

Category
Description
Email (optional, for follow-up)